Clinical Trial

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 23, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-08-16; most recent amendment 2024-08-21.
Status change: Recruiting → Active, Not Recruiting 2024-08-21
Status change: Not Yet Recruiting → Recruiting 2021-09-17
Trial Details
NCT Number NCT05007938
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Collaborators: The First Affiliated Hospital of Xiamen University
Conditions Non-Small Cell Lung Cancer
Enrollment 30 participants
Start Date 2021-08-12
Primary Completion 2024-12-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-23